Study and detection of potential markers for predicting metastasis into lymph nodes in prostate cancer.
Ioannis PapasotiriouPanagiotis ApostolouDimitrios-Athanasios NtanovasilisPanagiotis ParsonidisDaniar OsmonovKlaus-Peter JünemannPublished in: Biomarkers in medicine (2020)
Hormone-refractory prostate carcinoma has a different cell surface protein profile than hormone-sensitive prostate carcinoma, which provides migration ability and interactions with organs/tissues. Detection and association of these proteins with lymph node metastasis via lymphadenectomy might be beneficial for patients. Gene expression analysis in hormone-refractory and hormone-sensitive commercial cancer cell lines was performed and, after co-cultivation with osteoblasts or endothelial cells, knockdown experiments followed to validate potential biomarkers. "Myeloid-associated differentiation markers, myosin 1b and phosphatidylinositol-4-phosphate-5-kinase type 1 alpha are implicated in metastasis", their knockdown altered the expression of key regulators of endothelial-mesenchymal transition, invasion, motility and migration. In primary prostate tumors, these genes could be an indicator for future metastasis into lymph nodes.
Keyphrases
- prostate cancer
- lymph node
- lymph node metastasis
- papillary thyroid
- gene expression
- endothelial cells
- radical prostatectomy
- cell surface
- end stage renal disease
- benign prostatic hyperplasia
- squamous cell carcinoma
- binding protein
- bone marrow
- stem cells
- sentinel lymph node
- ejection fraction
- newly diagnosed
- poor prognosis
- dna methylation
- neoadjuvant chemotherapy
- prognostic factors
- immune response
- label free
- pseudomonas aeruginosa
- peritoneal dialysis
- genome wide
- tyrosine kinase
- protein kinase
- early stage
- escherichia coli
- real time pcr
- transcription factor
- robot assisted
- staphylococcus aureus
- high glucose
- genome wide identification
- climate change
- dendritic cells
- bioinformatics analysis